SG Americas Securities
NKTR icon

SG Americas Securities’s Nektar Therapeutics NKTR Stock Holding History

SG Americas Securities’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$233K Sell
3,235
-7,719
-70% -$440K ﹤0.01% 2571
2025
Q4 		$463K Buy
+10,954
New +$613K ﹤0.01% 2542
2025
Q2 		– Sell
-3,913
Closed -$40K – 3370
2025
Q1 		$40K Sell
3,913
-3,242
-45% -$42.4K ﹤0.01% 3291
2024
Q4 		$100K Buy
7,155
+779
+12% +$13.7K ﹤0.01% 2744
2024
Q3 		$124K Buy
6,376
+1,486
+30% +$28.3K ﹤0.01% 2892
2024
Q2 		$91K Buy
4,890
+1,889
+63% +$39.8K ﹤0.01% 2571
2024
Q1 		$42K Sell
3,001
-3,778
-56% -$39.5K ﹤0.01% 2790
2023
Q4 		$57K Buy
6,779
+1,588
+31% +$12K ﹤0.01% 2897
2023
Q3 		$46K Sell
5,191
-1,958
-27% -$18.8K ﹤0.01% 2958
2023
Q2 		$62K Sell
7,149
-4,649
-39% -$49.6K ﹤0.01% 2126
2023
Q1 		$124K Buy
11,798
+8,832
+298% +$267K ﹤0.01% 2777
2022
Q4 		$101K Buy
2,966
+1,555
+110% +$75.3K ﹤0.01% 2719
2022
Q3 		$68K Sell
1,411
-5,826
-81% -$347K ﹤0.01% 2943
2022
Q2 		$413K Buy
7,237
+2,181
+43% +$138K ﹤0.01% 2129
2022
Q1 		$409K Buy
+5,056
New +$748K ﹤0.01% 2007
2021
Q4 		– Sell
-3,421
Closed -$922K – 3668
2021
Q3 		$922K Sell
3,421
-1,542
-31% -$371K ﹤0.01% 1980
2021
Q2 		$1.28M Buy
4,963
+2,034
+69% +$563K 0.01% 1402
2021
Q1 		$879K Sell
2,929
-3,975
-58% -$1.24M ﹤0.01% 1640
2020
Q4 		$1.76M Buy
6,904
+5,469
+381% +$1.41M 0.01% 1170
2020
Q3 		$357K Sell
1,435
-1,594
-53% -$501K ﹤0.01% 1837
2020
Q2 		$1.05M Buy
3,029
+1,345
+80% +$420K 0.01% 1373
2020
Q1 		$451K Sell
1,684
-1,405
-45% -$435K ﹤0.01% 1923
2019
Q4 		$1M Sell
3,089
-1,128
-27% -$327K 0.01% 1263
2019
Q3 		$1.15M Buy
4,217
+1,175
+39% +$431K 0.01% 1323
2019
Q2 		$1.62M Sell
3,042
-6,657
-69% -$3.34M 0.01% 1145
2019
Q1 		$4.89M Buy
9,699
+8,869
+1,069% +$5.26M 0.05% 424
2018
Q4 		$409K Sell
830
-2,268
-73% -$1.37M ﹤0.01% 1996
2018
Q3 		$2.83M Buy
3,098
+192
+7% +$164K 0.02% 907
2018
Q2 		$2.13M Buy
2,906
+1,348
+87% +$1.55M 0.02% 907
2018
Q1 		$2.48M Buy
1,558
+883
+131% +$1.14M 0.02% 745
2017
Q4 		$604K Sell
675
-1,491
-69% -$882K 0.01% 1720
2017
Q3 		$780K Buy
2,166
+1,018
+89% +$318K 0.01% 1454
2017
Q2 		$337K Sell
1,148
-133
-10% -$38.4K ﹤0.01% 2098
2017
Q1 		$451K Sell
1,281
-2,707
-68% -$608K ﹤0.01% 1920
2016
Q4 		$734K Buy
3,988
+2,366
+146% +$481K 0.01% 1479
2016
Q3 		$418K Buy
+1,622
New +$418K ﹤0.01% 1876
2016
Q2 		– Sell
-1,145
Closed -$236K – 2871
2016
Q1 		$236K Buy
1,145
+689
+151% +$132K ﹤0.01% 2100
2015
Q4 		$115K Buy
+456
New +$93.8K ﹤0.01% 2341
2015
Q1 		– Sell
-1,546
Closed -$359K – 2913
2014
Q4 		$359K Buy
1,546
+261
+20% +$55.8K ﹤0.01% 1901
2014
Q3 		$233K Buy
1,285
+391
+44% +$74.8K ﹤0.01% 1904
2014
Q2 		$172K Buy
+894
New +$158K ﹤0.01% 2108
2013
Q4 		– Sell
-2,462
Closed -$386K – 2885
2013
Q3 		$386K Buy
+2,462
New +$455K ﹤0.01% 1760

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

SG Americas Securities's NKTR Position: Q1 2026 in Review

SG Americas Securities reduced its Nektar Therapeutics (NKTR) stake by 70% in Q1 2026, selling an estimated $440K and leaving 3,235 shares worth $233K. The position accounts for ﹤0.01% of the portfolio, ranked #2571.

SG Americas Securities first reported a position in NKTR in Q3 2013 and has held it in 42 quarters since. The position peaked at $4.89M in Q1 2019. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • SG Americas Securities held 3,235 shares of Nektar Therapeutics worth $233K as of Q1 2026.
  • SG Americas Securities sold 7,719 Nektar Therapeutics shares in Q1 2026, an estimated $440K.
  • Nektar Therapeutics made up ﹤0.01% of SG Americas Securities's portfolio in Q1 2026, its #2571 holding.
  • SG Americas Securities first reported a position in Nektar Therapeutics in Q3 2013 and has held it in 42 quarters since.
  • SG Americas Securities's Nektar Therapeutics position peaked at $4.89M in Q1 2019.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.